Efficacy and Safety of Minocycline in Acute Spontaneous Intracerebral Hemorrhage
ConditionIntracerebral Hemorrhage
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorBeijing Tiantan Hospital
About this trial
This is a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. It aims to evaluate the efficacy and safety of oral minocycline in patients with acute spontaneous intracerebral hemorrhage within 48 hours of onset.
Eligibility criteria
Qualifiers
CT-confirmed spontaneous supratentorial intracerebral hemorrhage;
Aged 18 to 80 years;
Within 48 hours of symptom onset;
Hematoma volume 15-40 ml;
Disqualifiers
Secondary intracerebral hemorrhage (traumatic, tumor-related, vascular malformation, aneurysm, coagulation disorder, etc.);
Intraventricular hemorrhage filling one entire lateral ventricle, third ventricle, or fourth ventricle, or more than half of two lateral ventricles;
Significant subarachnoid hemorrhage (Fisher grade ≥ 3) or subdural hemorrhage;
Patients with uncontrollable hypertension ( systolic blood pressure persistently ≥ 180 mmHg despite intensive antihypertensive treatment);
Trial design
Treatments tested in this trial
- Minocycline hydrochloride capsules
- Placebo capsules of Minocycline hydrochloride capsules
Treatment groups
1,192 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov